The Globe and Mail reports in its Saturday, May 6, edition that RBC analyst Walter Spracklin is holding on to his "sector perform" recommendation for Andlauer Healthcare Group. The Globe's David Leeder writes that Mr. Spracklin gave his share target a $2 trim to $51. Analysts on average target the shares at $56.68. Mr. Spracklin says in a note: "Andlauer has traded at a significant premium relative to peers due to: 1) attractive end-markets; 2) stable (and until now growing) margin; 3) clean balance sheet; 4) M&A upside; and 5) strong management ownership. As a result, our thesis has been that these factors would persist, the valuation premium is justified. ... But at recent valuation levels, the shares [are] fully valued. The Q1 results however suggested that 2022 margins were buoyed by rate premiums in U.S. TL which have 'diminished.' This rare miss and lowered expectations are being reflected in the share price performance today." The Globe reported on Nov. 11 and March 7 that Mr. Spracklin had reiterated his "sector perform" call for Andlauer when it could be had for $50.45 and $47.25. The Globe's Andrew Willis gushed over Andlauer's "dream team" on Nov. 15. The shares could then be had for $49.82.